A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of IMG-007 in Adult Alopecia Areata Participants

• Status: Active, not recruiting
• Trial end date: 2024-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of the study is to evaluate the safety of IMG-007 in adults with Alopecia Areata.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Inmagene LLC

Criteria

Key Inclusion Criteria:

• Male or female aged ≥ 18 and ≤ 65 years

• AA with current episode of hair loss of > 6 months but < 8 years

• AA with ≥ 50% scalp involvement as defined as SALT score ≥ 50

Key Exclusion Criteria:

• Known hepatitis B, hepatitis C, or human immunodeficiency virus infection

• Evidence of active or latent tuberculosis (TB)

• History of untreated or inadequately treated TB infection.

• Active infection requiring treatment with systemic antibiotics, antivirals, antifungals, antiparasitics or antiprotozoals at the Screening visit

• Concurrent hair loss due to other etiologies

• Primary "diffuse" type of AA

• Active inflammatory diseases on the scalp that would interfere with the assessment of AA

• History or presence of hair transplants or micropigmentation of the scalp

• Active systemic diseases that may cause hair loss

• Other conditions or laboratory abnormality that could increase the risk associated with study participation or could interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into the study.